RAPID

Project "RAPID" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

BunyaVax builds unprecedented technology for cost-effective and rapid development of vaccines against newly emerging viruses. The platform can be a valuable tool in quickly controlling the spread of new virus strains among populations. The timing of RAPID closely corresponds with a current focus of the vaccine industry on novel vaccine platform technologies that enable rapid response to emerging threats.

The BunyaVax RNA particle technology combines the efficacy of live vaccines with the safety of inactivated or subunit vaccines – which are currently the standard vaccine technologies. A unique characteristic of the RNA platform is that it allows for ‘plug and play’ application. Any gene can be plugged into the RNA particle genome to generate inherently safe and efficacious vaccines. The platform can stably express a broad variety of pathogen derived antigens. A major advantage is that development and manufacturing can be completed in a timeframe of 16 weeks which is at least twice as fast as current methods. The BunyaVax technology is in a stage of proven efficacy in sheep.

RAPID is designed to prepare for partnerships with vaccine manufacturers and/or venture capital firms and to lay the foundation for clinical application of the vaccine platform. Key steps for upscaled production levels will be taken.

The innovation project is at the core of the strategy of BunyaVax. The project is instrumental for reaching a stage in which commercial partnerships can be explored. Ultimately, this will allow BunyaVax to forward the technology to a stage in which industry can use it to develop vaccines for controlling veterinary and human infectious disease outbreaks at an earlier stage than currently possible.